Knight Therapeutics (TSE:GUD) Reaches New 52-Week High – Still a Buy?

Knight Therapeutics Inc. (TSE:GUD)’s stock price reached a new 52-week high during trading on Thursday. The stock traded as high as C$11.71 and last traded at C$11.70, with a volume of 70,523 shares. The stock had previously closed at C$11.45.

Knight Therapeutics Trading Up 2.2%

The company has a 50 day simple moving average of C$10.18 and a 200 day simple moving average of C$9.30. The company has a market capitalization of C$1.15 billion, a PE ratio of 78.00, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.45. The company has a debt-to-equity ratio of 4.29, a quick ratio of 1.79 and a current ratio of 2.28.

Knight Therapeutics (TSE:GUD) last released its earnings results on Thursday, August 6th. The company reported C($0.03) earnings per share for the quarter. The firm had revenue of C$143.97 million during the quarter. Knight Therapeutics had a net margin of 2.72% and a return on equity of 1.91%. Analysts anticipate that Knight Therapeutics Inc. will post 0.10 earnings per share for the current year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.